论文部分内容阅读
目的探讨尿激酶静脉注射联合卡托普利治疗老年急性心肌梗死的临床效果及其安全性。方法 2009年6月至2011年6月治疗的老年急性心肌梗死患者128例,按其治疗方法分为观察组68例,接受尿激酶静脉注射联合卡托普利治疗;对照组60例,接受尿激酶静脉注射治疗。以疾病体征变化、血清肌酸激酶同工酶(CK-MB)水平和白细胞计数作为评价疗效的指标。同时比较两组的不良反应发生情况和发生率。结果观察组可快速改善心肌梗死体征,快速缓和患者的疾病痛苦,且心前区疼痛复发率低。联合治疗组的CK-MB在较短时间(9.5 h)内即可达到峰值,且迅速下降至正常水平。联合治疗可逆转单独治疗中的白细胞计数和中性粒细胞计数的不正常情况。结论尿激酶静脉注射联合卡托普利治疗老年急性心肌梗死效果显著,且不良反应低,可大量应用于临床。
Objective To investigate the clinical effects and safety of intravenous injection of urokinase combined with captopril in elderly patients with acute myocardial infarction. Methods A total of 128 elderly patients with acute myocardial infarction who were treated from June 2009 to June 2011 were divided into observation group (68 cases) and urokinase intravenous injection combined with captopril (60 cases). The control group received urine Kinase intravenous therapy. Changes in disease signs, serum creatine kinase (CK-MB) levels and white blood cell count as an indicator of efficacy. At the same time, the occurrence and incidence of adverse reactions in both groups were compared. Results The observation group can quickly improve the signs of myocardial infarction, quickly alleviate the suffering of patients with disease, and precordial pain recurrence rate is low. CK-MB in the combined treatment group peaked in a short period of time (9.5 h), and rapidly decreased to normal levels. Combination therapy reverses the abnormalities of white blood cell count and neutrophil count in monotherapy. Conclusion The combination of intravenous injection of urokinase and captopril has significant effect on the treatment of acute myocardial infarction in the elderly. The adverse reaction is low and can be widely used in clinic.